Lead Product(s) : Carisbamate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Carisbamate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Seizures.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 02, 2022
Lead Product(s) : Carisbamate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Carisbamate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
SK life Science Initiates Phase 3 Clinical Trial of Carisbamate for Lennox-Gastaut Syndrome
Details : Phase 3 clinical trial initiated to evaluate the efficacy and safety of YKP509 (carisbamate) for the treatment of seizures associated with LGS. Carisbamate has also received orphan drug designation from the FDA.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 06, 2022
Lead Product(s) : Carisbamate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Carisbamate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : PRA Health Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioavailability and Food Effect Study of 3 Types of Carisbamate
Details : Carisbamate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 20, 2020
Lead Product(s) : Carisbamate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : PRA Health Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Carisbamate
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome
Details : Carisbamate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lennox Gastaut Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 20, 2019
Lead Product(s) : Carisbamate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Carisbamate
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome
Details : Carisbamate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lennox Gastaut Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 06, 2018
Lead Product(s) : Carisbamate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable